Found: 23
Select item for more details and to access through your institution.
Naturally occurring systemic immune responses to HPV antigens do not predict regression of CIN2/3.
- Published in:
- Cancer Immunology, Immunotherapy, 2010, v. 59, n. 5, p. 799, doi. 10.1007/s00262-009-0806-4
- By:
- Publication type:
- Article
Enhancing dendritic cell vaccine potency by combining a BAK/BAX siRNA-mediated antiapoptotic strategy to prolong dendritic cell life with an intracellular strategy to target antigen to lysosomal compartments.
- Published in:
- International Journal of Cancer, 2007, v. 120, n. 8, p. 1696, doi. 10.1002/ijc.22377
- By:
- Publication type:
- Article
Moderate Reduction of γ-Secretase Attenuates Amyloid Burden and Limits Mechanism-Based Liabilities.
- Published in:
- Journal of Neuroscience, 2007, v. 27, n. 40, p. 10849, doi. 10.1523/JNEUROSCI.2152-07.2007
- By:
- Publication type:
- Article
Enhancing antitumor immunogenicity of HPV16-E7 DNA vaccine by fusing DNA encoding E7-antigenic peptide to DNA encoding capsid protein L1 of Bovine papillomavirus.
- Published in:
- Cell & Bioscience, 2017, v. 7, p. 1, doi. 10.1186/s13578-017-0171-5
- By:
- Publication type:
- Article
Identification of human MHC-I HPV18 E6/E7-specific CD8 + T cell epitopes and generation of an HPV18 E6/E7-expressing adenosquamous carcinoma in HLA-A2 transgenic mice.
- Published in:
- Journal of Biomedical Science, 2022, v. 29, n. 1, p. 1, doi. 10.1186/s12929-022-00864-5
- By:
- Publication type:
- Article
Control of Spontaneous HPV16 E6/E7 Expressing Oral Cancer in HLA-A2 (AAD) Transgenic Mice with Therapeutic HPV DNA Vaccine.
- Published in:
- Journal of Biomedical Science, 2021, v. 28, n. 1, p. 1, doi. 10.1186/s12929-021-00759-x
- By:
- Publication type:
- Article
Immunologic Control of Mus musculus Papillomavirus Type 1.
- Published in:
- PLoS Pathogens, 2015, v. 11, n. 10, p. 1, doi. 10.1371/journal.ppat.1005243
- By:
- Publication type:
- Article
Characterization of human papillomavirus type 11-specific immune responses in a preclinical model.
- Published in:
- Laryngoscope, 2010, v. 120, n. 3, p. 504, doi. 10.1002/lary.20745
- By:
- Publication type:
- Article
Sequential Cisplatin Therapy and Vaccination with HPV16 E6E7L2 Fusion Protein in Saponin Adjuvant GPI-0100 for the Treatment of a Model HPV16+ Cancer.
- Published in:
- PLoS ONE, 2015, v. 10, n. 1, p. 1, doi. 10.1371/journal.pone.0116389
- By:
- Publication type:
- Article
Stressing the Ubiquitin-Proteasome System without 20S Proteolytic Inhibition Selectively Kills Cervical Cancer Cells.
- Published in:
- PLoS ONE, 2011, v. 6, n. 8, p. 1, doi. 10.1371/journal.pone.0023888
- By:
- Publication type:
- Article
Combination of proteasome and HDAC inhibitor enhances HPV16 E7-specific CD8<sup>+</sup> T cell immune response and antitumor effects in a preclinical cervical cancer model.
- Published in:
- Journal of Biomedical Science, 2015, v. 22, n. 1, p. 129, doi. 10.1186/s12929-014-0111-1
- By:
- Publication type:
- Article
Vascular disrupting agent DMXAA enhances the antitumor effects generated by therapeutic HPV DNA vaccines.
- Published in:
- Journal of Biomedical Science, 2011, v. 18, n. 1, p. 21, doi. 10.1186/1423-0127-18-21
- By:
- Publication type:
- Article
Characterization of HPV-16 E6 DNA vaccines employing intracellular targeting and intercellular spreading strategies.
- Published in:
- Journal of Biomedical Science, 2005, v. 12, n. 5, p. 689, doi. 10.1007/s11373-005-9012-3
- By:
- Publication type:
- Article
PD-1 blockade synergizes with intratumoral vaccination of a therapeutic HPV protein vaccine and elicits regression of tumor in a preclinical model.
- Published in:
- Cancer Immunology, Immunotherapy, 2021, v. 70, n. 4, p. 1049, doi. 10.1007/s00262-020-02754-x
- By:
- Publication type:
- Article
Identification of the murine H-2D and human HLA-A*0201 MHC class I-restricted HPV6 E7-specific cytotoxic T lymphocyte epitopes.
- Published in:
- Cancer Immunology, Immunotherapy, 2016, v. 65, n. 3, p. 261, doi. 10.1007/s00262-016-1793-x
- By:
- Publication type:
- Article
Low-dose cyclophosphamide administered as daily or single dose enhances the antitumor effects of a therapeutic HPV vaccine.
- Published in:
- Cancer Immunology, Immunotherapy, 2013, v. 62, n. 1, p. 171, doi. 10.1007/s00262-012-1322-5
- By:
- Publication type:
- Article
Structure-function analyses of candidate small molecule RPN13 inhibitors with antitumor properties.
- Published in:
- PLoS ONE, 2020, v. 15, n. 1, p. 1, doi. 10.1371/journal.pone.0227727
- By:
- Publication type:
- Article
Optimization of heterologous DNA-prime, protein boost regimens and site of vaccination to enhance therapeutic immunity against human papillomavirus-associated disease.
- Published in:
- Cell & Bioscience, 2016, v. 6, p. 1, doi. 10.1186/s13578-016-0080-z
- By:
- Publication type:
- Article
Co-administration with DNA encoding papillomavirus capsid proteins enhances the antitumor effects generated by therapeutic HPV DNA vaccination.
- Published in:
- Cell & Bioscience, 2015, v. 5, n. 1, p. 1, doi. 10.1186/s13578-015-0025-y
- By:
- Publication type:
- Article
Prophylactic immunization with human papillomavirus vaccines induces oral immunity in mice.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Immunologic responses to a novel DNA vaccine targeting human papillomavirus-11 E6E7.
- Published in:
- 2017
- By:
- Publication type:
- journal article
MHC-Ig induces memory T cell formation in vivo and inhibits tumour growth.
- Published in:
- Immunity, Inflammation & Disease, 2014, v. 2, n. 3, p. 181, doi. 10.1002/iid3.35
- By:
- Publication type:
- Article
Differential expression of epidermal growth factor receptor in juvenile and adult-onset recurrent respiratory papillomatosis Correspondence.
- Published in:
- Histopathology, 2010, v. 57, n. 5, p. 768, doi. 10.1111/j.1365-2559.2010.03691.x
- By:
- Publication type:
- Article